DAVID NELSON to Hepatitis C, Chronic
This is a "connection" page, showing publications DAVID NELSON has written about Hepatitis C, Chronic.
Connection Strength
1.761
-
Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection. Sci Rep. 2022 10 27; 12(1):18094.
Score: 0.595
-
Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. JAMA Netw Open. 2019 06 05; 2(6):e194765.
Score: 0.470
-
The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver Int. 2012 Feb; 32 Suppl 1:103-7.
Score: 0.283
-
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology. 2021 12; 74(6):2952-2964.
Score: 0.137
-
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017 10 12; 377(15):1448-1455.
Score: 0.105
-
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1594-603.
Score: 0.082
-
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol. 2007 Jul; 47(1):51-9.
Score: 0.050
-
Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology. 2003 May; 37(5):1180-8.
Score: 0.039